Pdt Partners, LLC Passage Bio, Inc. Transaction History

Pdt Partners, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.63 - $3.46 $39,956 - $84,814	-24,513 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$2.66 - $6.49 $30,414 - $74,206	11,434 Added 87.42%	24,513 $76,000
Q4 2021 Feb 14, 2022	BUY	$6.24 - $10.2 $13,653 - $22,317	2,188 Added 20.09%	13,079 $83,000
Q3 2021 Nov 15, 2021	SELL	$9.73 - $15.52 $8,348 - $13,316	-858 Reduced 7.3%	10,891 $108,000
Q2 2021 Aug 16, 2021	BUY	$12.44 - $19.45 $146,157 - $228,518	11,749 New	11,749 $156,000

38.7M

7.7K

Ticker PASG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,463,200
Market Cap $35.9M
Description
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.